An article in the July 16, 2004, issue of BioWorld Today should have said Neurobiological Technologies is acquiring Empire Pharmaceuticals for a total of $22.8 million, half of which it paid now through 2.4 million NTI shares and $2 million in cash. The other 2.4 million shares and $2 million in cash would be paid if Viprinex's Phase III trials begin as planned.

Editor's Note: The correction has been made in BioWorld Online.

No Comments